News Agency
The Times

Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in Innovative Drug Project

  • Written by PR Newswire

SHANGHAI, July 26, 2024 /PRNewswire/ -- On July 15, Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in the United States. This clinical trial, known as LOTUS, is an open-label, multicenter, single-dose, dose-escalation clinical trial via...

Read more: Sanyou Bio Congratulates Eluminex Biosciences and Foreseen Biotechnology on Major Breakthroughs in...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion